Annual Drug Patent Expirations for GLYXAMBI
Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for GLYXAMBI.
This drug has two hundred and twenty patent family members in forty-three countries.
The generic ingredient in GLYXAMBI is empagliflozin; linagliptin. One supplier is listed for this compound. Additional details are available on the empagliflozin; linagliptin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
